<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="137849">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01886781</url>
  </required_header>
  <id_info>
    <org_study_id>N10-08-270</org_study_id>
    <nct_id>NCT01886781</nct_id>
  </id_info>
  <brief_title>Effect of Lactobacillus Plantarum 299v on Symptoms of Irritable Bowel Syndrome</brief_title>
  <official_title>Randomised Controlled Trial: Effect of Lactobacillus Plantarum 299v on Symptoms of Irritable Bowel Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Stellenbosch</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nestle Nutrition Institute Africa (NNIA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Research Foundation (NRF) (RSA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Stellenbosch</source>
  <oversight_info>
    <authority>South Africa: Health Research Ethics Committee, University of Stellenbosch</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients with IBS, will supplementation with a probiotic influence gut microflora and
      thus improve clinical outcomes, as compared to no intervention?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Conduct a study on dietary intake and link variations in colon microflora to dietary
      composition, faecal SCFAs and pathological markers of the colon.

      Conduct an appropriately well designed randomised, double blind, placebo-controlled clinical
      trial with L.plantarum 299v.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2011</start_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>A decrease in abdominal pain</measure>
    <time_frame>Total trial period 12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The clinical severity of the IBS symptoms (pain and distension) was evaluated by the Francis Severity Score questionnaire (Francis 1997). The questionnaire is a validated tools for use in IBS.  The severity score contained five questions, each given a value from 0 (no symptoms) to 100 (most severe) for measuring the severity and frequency of abdominal pain.  The sum of scores of these questions was considered the severity score, with a maximum possible score of 500</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">81</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Lactobacillus plantarum 299v</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lactobacillus plantarum 299v</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crytalline cellulose powder</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lactobacillus plantarum 299v</intervention_name>
    <arm_group_label>Lactobacillus plantarum 299v</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Crytalline cellulose powder</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  fulfillment of the Rome II criteria for IBS,

          -  availability of at least one colonoscopy within the last three years,

          -  aged 18 or older at the time of screening,

          -  provision of written informed consent,

          -  commitment of availability throughout the 12 week study period.

        Exclusion Criteria:

          -  major abdominal surgery in the past other than other than appendectomy, caesarean
             section, tubal laparoscopic cholecystectomy, abdominal wall hernia repair or/and
             hysterectomy,

          -  current use of antibiotics,

          -  history of organic intestinal disease,

          -  pregnant or breastfeeding mothers,

          -  chronic infectious disease like HIV or tuberculosis, and

          -  unable to understand English or Afrikaans.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cheryl Stevenson, M.Sc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univeristy of Stellenbosch</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cheryl Stevenson, M.Sc</last_name>
    <phone>+270827514411</phone>
    <email>cheryl@retaildc.co.za</email>
  </overall_contact>
  <location>
    <facility>
      <name>Netcare Greenacres Hospital</name>
      <address>
        <city>Port Elizabeth</city>
        <state>Eastern Cape</state>
        <zip>6001</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Cheryl Stevenson, M.Sc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 21, 2013</lastchanged_date>
  <firstreceived_date>June 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Stellenbosch</investigator_affiliation>
    <investigator_full_name>Cheryl Stevenson</investigator_full_name>
    <investigator_title>Mrs</investigator_title>
  </responsible_party>
  <keyword>only constipation and diarrhea predominant</keyword>
  <keyword>no mixed or alternating types</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
